3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Neoplasms
15
Endometrial Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Rectal Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Colonic Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Osteosarcoma
2
Locally Advanced Rectal Cancer (LARC)
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Interventions
Carboplatin
5
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
sarilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
dostarlimab
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled